文献速递传染病防控与疫情报告免疫规划

第三代猴痘疫苗对猴痘及疾病严重程度的疫苗有效性:系统综述与Meta分析

Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2024-06-21

该系统综述与Meta分析共纳入33项第三代猴痘疫苗研究(32项为MVA-BN),主要针对2022年5-10月18-49岁男男性行为者。单剂MVA-BN疫苗有效性为76%(95%CI 64-88%),两剂为82%(95%CI 72-92%),暴露后预防有效性为20%(95%CI -24-65%)。结论认为单剂和两剂MVA-BN对预防猴痘均高度有效,但暴露后预防的估计受永生时间偏倚、猴痘主要传播模式和实际接种时机限制。

要点

  • 单剂MVA-BN疫苗有效性为76%(95%CI 64-88%),基于12项研究。
  • 两剂MVA-BN疫苗有效性为82%(95%CI 72-92%),基于6项研究。
  • MVA-BN暴露后预防有效性为20%(95%CI -24-65%),基于7项研究。

核心结论

  • 单剂和两剂MVA-BN疫苗对预防猴痘均高度有效。
  • 暴露后预防的有效性估计受永生时间偏倚、猴痘主要传播模式和实际接种时机限制。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Web of Science、Google Scholar、Embase、MedRxiv和灰色文献,从1970年1月1日至2023年11月3日。
  • 纳入33项第三代猴痘疫苗研究,其中32项为MVA-BN;另有两项为现有数据的再分析。
  • 大多数研究聚焦于2022年5月至10月期间18-49岁的男男性行为者。
  • 纳入标准为测量人类疫苗效力或有效性的研究,排除动物研究和免疫原性研究。

主要发现

  • 单剂MVA-BN疫苗有效性为76%(95%CI 64-88%),基于12项研究。
  • 两剂MVA-BN疫苗有效性为82%(95%CI 72-92%),基于6项研究。
  • MVA-BN暴露后预防对猴痘的有效性为20%(95%CI -24-65%),基于7项研究。
  • 所有疫苗有效性均采用随机效应估计计算。
  • 33项研究中,18项(55%)质量评为差,3项(9%)评为一般,12项(36%)评为好;纳入Meta分析的16项研究中11项(69%)质量评为好。

关键数值与推荐

  • 单剂MVA-BN疫苗有效性为76%(95%CI 64-88%)。
  • 两剂MVA-BN疫苗有效性为82%(95%CI 72-92%)。
  • MVA-BN暴露后预防有效性为20%(95%CI -24-65%)。

局限性

  • 暴露后预防的有效性估计受永生时间偏倚限制。
  • 暴露后预防的有效性估计受猴痘主要传播模式限制。
  • 暴露后预防的有效性估计受实际接种时机限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Before the global mpox outbreak which began in 2022, the real-world vaccine effectiveness (VE) of mpox vaccines was unknown. We quantified the VE in the global population of 3rd generation or later mpox vaccines (MVA-BN, LC16m8, OrthopoxVac) compared with unvaccinated or other vaccinated states for infection, hospitalization and death. VE was stratified by 1-dose and 2-doses and post-exposure prophylaxis (PEP). METHODS: Studies were included if they measured vaccine efficacy or effectiveness in humans. Animal studies and immunogenicity studies were excluded. MEDLINE, Web of Science, Google Scholar, Embase, MedRxiv and grey literature were searched from January 1st, 1970, with the last search run on November 3, 2023 (Prospero, CRD42022345240). Risk of publication bias was assessed via funnel plots and Egger's test, and study quality via Newcastle-Ottawa scales. RESULTS: A total of 11,892 records were identified via primary search, 3,223 via citation chasing. Thirty-three studies were identified of 3rd generation vaccines, 32 of which were MVA-BN. Two additional studies were re-analysis of existing data. Most of these studies were focused on gay, bisexual, or other men who have sex with men between the ages of 18-49 in May to October of 2022. VE of 1 dose of MVA-BN was 76% (95%CI 64-88%) from twelve studies. VE of 2 doses was 82% (95%CI 72-92%) from six studies. VE of MVA-BN PEP against mpox was 20% (95%CI -24-65%) from seven studies. All VE are calculated from random effects estimates. 18/33(55%) studies were rated as poor, 3/33(9%) as fair and 12/33(36%) as good. Studies included in the meta-analysis had higher quality: 11/16 (69%) were rated as good quality. CONCLUSION: Both 1 and 2 doses of MVA-BN are highly effective at preventing mpox. Effectiveness estimates, specifically of PEP are limited by immortal time bias, predominant mode of mpox transmission, and real-world vaccine timing of administration.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pischel L, Martini BA, Yu N, et al. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine. 2024. PMID: 38906763. doi:10.1016/j.vaccine.2024.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。